Amelioration of Anemia in the ICGN Mouse, a Renal Anemia Model, with a Subcutaneous Bolus Injection of Erythropoietin Adsorbed to Hydroxyapatite Matrix. The Journal of veterinary medical science / the Japanese Society of Veterinary Science [J Vet Med Sci] Journal article | | Title | Amelioration of Anemia in the ICGN Mouse, a Renal Anemia Model, with a Subcutaneous Bolus Injection of Erythropoietin Adsorbed to Hydroxyapatite Matrix. | | Author(s) | Nagasaki K, Ikoma T, Katsuda S, Tonegawa T, Tanaka J, Ohyama M, Hayashida K, Nakamura T, Sato H, Ito S, Sasaki N, Agui T | | Institution | Laboratory of Laboratory Animal Science and Medicine, Department of Disease Control, Hokkaido University. | | Source | J Vet Med Sci 2009 Oct; 71(10):1365-71. | | Abstract | The recombinant human erythropoietin (rhEPO) is used for the treatment of patients with renal anemia. However, rhEPO should be administered subcutaneously or intravenously three times a week. The repetitive injections of rhEPO result in burdens to patients. To resolve this problem, we investigated the sustaining release methods using an rhEPO-hydroxyapatite (HAp) made by spray-drying technique as the drug delivery system. Two types of rhEPO-HAp formulations were prepared; zinc (Zn) formulation and Zn and poly-L-lactic acid (PLA) formulation. These formulations were examined in genetically anemic model, ICGN (ICR-derived glomerulonephritis) mice. According to in vivo release test of rhEPO from HAp in ICGN mice, elevated plasma concentration of rhEPO could be maintained for more than 7 days. These mice showed the amelioration of anemia for more than 3 weeks post-administration without causing any side effect. In conclusion, Zn or Zn/PLA formulation of HAp was considered to be one of the useful carriers of rhEPO for long-term improvement of anemia. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19887744 |
|
|
| |
Advertise on this site.
| | |
|
